Acute responses to phytoestrogens in small arteries from men with coronary heart disease

2006 ◽  
Vol 290 (5) ◽  
pp. H1969-H1975 ◽  
Author(s):  
Maria Natalia Cruz ◽  
Leonid Luksha ◽  
Henareh Logman ◽  
Lucilla Poston ◽  
Stefan Agewall ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ex Vivo ◽  
Subcutaneous Fat ◽  
Estrogen Receptor Α ◽  
Response Curves ◽  
Small Arteries ◽  
Before And After ◽  
Established Coronary Heart Disease ◽  
Normal Men

The aim of this study was to investigate acute vasodilator responses to phytoestrogens and selective estrogen receptor-α (ERα) agonist in isolated small arteries from men with established coronary heart disease (CHD) and with a history of myocardial infarction versus healthy male control subjects. As to methodology, small arteries obtained from subcutaneous fat biopsies and mounted on a wire myograph were preconstricted with norepinephrine, and dilator responses to increasing nanomolar-micromolar concentrations of the phytoestrogens resveratrol and genistein (predominantly ERβ agonists) and to propyl-[1H]-pyrazole-1,3,5-triyl-trisplenol (PPT, a selective ERα agonist) were determined. These were compared with responses to reference compound 17β-estradiol (17β-E2). Concentration-response curves were constructed before and after nitric oxide (NO) synthase inhibition with Nω-nitro-l-arginine methyl ester. As a result, relaxation induced by the investigated compounds was similar in men with CHD and control men, but in both groups PPT and genistein-induced relaxation was greater than that of resveratrol and 17β-E2. NO contributed to both phytoestrogens and PPT-induced relaxation but not to 17β-E2 responses in arteries from control men. This NO-mediated component of relaxation was absent in arteries from men with established CHD. In conclusion, phytoestrogens, at concentrations achievable by ingestion of phytoestrogen-rich food products, evoke dilatation ex vivo of small peripheral arteries from normal men and those with established CHD. The contribution of NO to dilatory responses by these compounds is pertinent to arteries from control males, whereas other NO-independent dilatory mechanism(s) are involved in arteries from CHD.

Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease

2008 ◽  
Vol 196 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Maria Natalia Cruz ◽  
Stefan Agewall ◽  
Karin Schenck-Gustafsson ◽  
Karolina Kublickiene
Keyword(s):  
Coronary Heart Disease ◽  
Estrogen Receptor ◽  
Heart Disease ◽  
Receptor Subtypes ◽  
Small Arteries

scholarly journals Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study

2018 ◽  
Vol 270 ◽  
pp. 21-27 ◽  
Author(s):  
Jean Ferrières ◽  
Dominik Lautsch ◽  
Baishali M. Ambegaonkar ◽  
Gaetano M. De Ferrari ◽  
Ami Vyas ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Established Coronary Heart Disease

Genetic Polymorphisms, LDL-C and sdLDL-C Help Optimize Coronary Heart Disease (CHD) Therapy

2021 ◽  
Author(s):  
Ruozhu Dai ◽  
Huilin Zhuo ◽  
Wei Wang ◽  
Xinjun Wang ◽  
Xiaoyu Zhao
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Genetic Polymorphisms ◽  
Therapy Monitoring ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Healthy People ◽  
Risk Indicator ◽  
Before And After ◽  
A Prospective Study

Abstract Background: Low-density lipoprotein cholesterol (LDL-C) and small, dense LDL-C (sdLDL-C) are important risk indicator of coronary heart disease (CHD), but their application in therapy monitoring of CHD is still far from being elucidated. Following the concept of precision medicine, we investigated whether the scientific medication based on medication-sensitive genes can reverse the LDL-C and sdLDL-C status in human bloodstream, so as to reveal the possibility of them as a monitoring indicator of CHD efficacy.Methods: A prospective study of CHD cohort containing 208 Chinese CHD patients (158 males and 50 females) and 20 healthy people (14 males and 6 females) was recruited. LDL-C and its subfractions were detected before and after treatment. Polymorphism of medication-sensitive genes, including SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were detected for medication guidance.Results: Nearly half of Chinese CHD patients (47.60%, 99/208) had genetic polymorphisms with homozygous or heterozygous mutations within these three genes. LDL-1 and LDL-2, subfractions of LDL-C, had a 100% positive rate in CHD patients and healthy people. However, sdLDL-C components of LDL-5 to LDL-7 were only enrichment in CHD patients. Moreover, the mean amount of sdLDL-C subfractions in CHD patients was significantly higher than that in healthy people. Among 180 patients with treatment remission, 81.67% (n=147) of CHD patients had decreased LDL-C, while 61.67% (n=111) of patients had decreased sdLDL-C.Conclusion: sdLDL-C has better accuracy on CHD screening than LDL-C, while LDL-C was more suitable for CHD therapy monitoring. Combined medication-sensitive genes polymorphism, LDL-C and sdLDL-C detection would optimize the treatment strategy for CHD patients.

Treatment with Simvastatin and Low-dose Aspirin Depresses Thrombin Generation in Patients with Coronary Heart Disease and Borderline-high Cholesterol Levels

2001 ◽  
Vol 85 (02) ◽  
pp. 221-225 ◽  
Author(s):  
Anetta Undas ◽  
Robert Undas ◽  
Jan Brożek ◽  
Andrzej Szczeklik ◽  
Jacek Musiał
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Thrombin Generation ◽  
Low Dose ◽  
Ex Vivo ◽  
Blood Cholesterol ◽  
High Cholesterol ◽  
Cholesterol Levels ◽  
Dose Aspirin ◽  
Low Dose Aspirin

SummaryAspirin and statins are beneficial in coronary heart disease across a broad range of cholesterol levels. We assessed the effects of low-dose aspirin (75 mg daily) on thrombin generation in patients with coronary heart disease and average blood cholesterol levels. We also investigated whether in patients with borderline-high cholesterol level who have been already taking aspirin, additional treatment with simvastatin would affect thrombin generation.Seven-day treatment with low-dose aspirin decreased thrombin generation ex vivo only in patients with total cholesterol 5.2 mmol/L. In patients with higher cholesterol levels aspirin had no effect. In these patients, already taking low-dose aspirin, additional three-month simvastatin treatment resulted in a reduction of thrombin generation. This demonstrates that low-dose aspirin depresses thrombin generation only in subjects with desirable blood cholesterol levels, while in others, with borderline-high cholesterol, thrombin formation is being reduced following the addition of simvastatin.

Effectiveness of Long-term Heparin-induced Extracorporeal LDL Precipitation (HELP) in Improving Coronary Calcifications

2003 ◽  
Vol 26 (3) ◽  
pp. 252-255 ◽  
Author(s):  
A. Ramunni ◽  
L.F. Morrone ◽  
G. Baldassarre ◽  
E. Montagna ◽  
A. Saracino ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Evidence ◽  
Ldl Cholesterol ◽  
Clinical Manifestations ◽  
Mean Value ◽  
Mean Values ◽  
Plasma Pool ◽  
Before And After

There is clear clinical evidence that a drastic lowering of plasma LDL- Cholesterol (LDL) concentrations significantly reduces the rate of total and coronary mortality as well as the incidence of cardiovascular events in high risk hypercholesterolemic patients. We describe the case of a 51-year-old woman with coronary heart disease (CHD) who presented with increasing angina on exertion in 1995, at the age of 45. She suffered from a heterozygous familial hypercholesterolemia and in 1985 her total cholesterol (TCHO) was 328±62 mg/dl (mean value of ten analysis). After ten years of statins her mean values (20 analysis, 2 per year) were: TCHO 259±71, LDL 209±47, HDL 35±7 mg/dl. Coronary angiography (CA) performed in 1995 disclosed three vessel coronary heart disease with significant stenoses of the distal right coronary artery, multiple calcifications of the interventricularis artery and multiple plaques with significant stenoses in the ramus circumflexus. The woman underwent coronary by-pass surgery. Thereafter the patient was treated for six years with HELP in biweekly intervals, in combination with statins. TCHO, LDL, HDL and fibrinogen (fb) levels were measured before and after each treatment. Their mean values for an amount of 120 sessions were: TCHO pre 216±23, post 111±18 LDL pre 152±16 post 67±18, HDL pre 42±5 post 35±4 fb pre 306±48 post 125±31. In 2001 a new CA was performed. Calcifications disappeared and stenoses were identical to the previous CA or reduced. There were no further clinical manifestations of CHD. We trust that the clinical benefit of the HELP procedure will be substantial for those patients who have problems in clearing LDL from their plasma pool and who are at the same time sensitive to elevated LDL levels by the development of premature coronary sclerosis.

scholarly journals Latent Coronary Heart Disease Detected by Electrocardiogram Before and After Exercise

BMJ ◽  
1963 ◽  
Vol 1 (5328) ◽  
pp. 423-428 ◽  
Author(s):  
A. Rumball ◽  
E. D. Acheson
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Before And After
Sign in / Sign up

Export Citation Format

Share Document